🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Non-Muscle Invasive Bladder Carcinoma

Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy NCT07144319n/a8 sites📍 Tampa📍 Ann Arbor📍 New Brunswick Photocure Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer NCT07474519Phase 41 site📍 Columbus Ohio State University Comprehensive Cancer Center · Tests: Accelerometry, BCG Solution, BCG Solution, BCG Solution, Electronic Health Record Review Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection NCT06525571Phase 32 sites📍 Washington D.C.📍 Baltimore Johns Hopkins University · Tests: Cysview, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) NCT07222488Phase 1, Phase 217 sites📍 Bakersfield📍 New Brunswick📍 Myrtle Beach Merck Sharp & Dohme LLC · Tests: MK-3120 Chemoablation for Low-Grade Bladder Cancer NCT07019220Phase 21 site📍 Vienna Ekaterina Laukhtina · Tests: Gemcitabine Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer NCT06995677Phase 248 sites📍 Homewood📍 Little Rock📍 Murrieta Tyra Biosciences, Inc · Tests: TYRA-300 60mg, TYRA-300 50mg, TYRA-300 Dose 70 mg Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer NCT07646145Phase 21 site📍 Taiyuan Shanxi Province Cancer Hospital · Tests: Disitamab Vedotin, Mitomycin C (MMC) The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy NCT06388720Phase 21 site📍 Goyang-si National Cancer Center, Korea · Tests: Mitomycin-C, gemcitabine Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer NCT07187635NA7 sites📍 Nanchang📍 Guangzhou📍 Xingtai Tianjin Medical University Second Hospital · Tests: Second Transurethral Resection of Bladder Tumor (re-TURBT), utDNA Testing (Urine Tumor DNA Detection) The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection NCT06287541NA1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Urine biomarker -Guided without reTURBT Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer NCT07475403Phase 23 sites📍 Tianjin📍 Tianjin📍 Xingtai Tianjin Medical University Second Hospital · Tests: Systemic immunotherapy A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer NCT07122414Phase 1, Phase 212 sites📍 Beijing📍 Beijing📍 Fuzhou Suzhou Forlong Biotechnology Co., Ltd · Tests: FL115, FL115+BCG PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer NCT06173349Phase 11 site📍 Sacramento University of California, Davis · Tests: PLZ4-coated paclitaxel loaded micelles (PPM) LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve NCT04752722Phase 1, Phase 2102 sites📍 Birmingham📍 Scottsdale📍 Tucson enGene, Inc. · Tests: EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (Substudy) Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy NCT07000084Phase 360 sites📍 Birmingham📍 Fairbanks📍 Gilbert Alliance for Clinical Trials in Oncology · Tests: BCG Solution, Biopsy of Bladder, Cystoscopy, Computed Tomography, Magnetic Resonance Imaging Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment NCT05126472Phase 1, Phase 27 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: anti-CD40 antibody 2141-V11, anti-CD40 antibody 2141-V11, anti-CD40 antibody 2141-V11, Intravesical Gemcitabine, Intrav… A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC) NCT06108492Phase 11 site📍 Shanghai Shanghai Hengrui Pharmaceutical Co., Ltd. · Tests: SHR-2005 Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer NCT03379909Phase 23 sites📍 Nijmegen📍 Rotterdam📍 Amsterdam Academisch Medisch Centrum - Universiteit van Amsterdam (AM… · Tests: Metformin A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer NCT06503614Phase 25 sites📍 San Francisco📍 Tampa📍 New Brunswick John Sfakianos · Tests: Durvalumab, Monalizumab Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG NCT05672615n/a1 site📍 Washington D.C. Johns Hopkins University · Tests: Questionnaires, Daily Mood Diaries, Urine Specimen Collection, Research Blood Draw, Utilize excess tissue from a standa… Tumor Staging T of Bladder Tumours: Correlation of MRI and Anatomopathologic Analysis NCT05464576NA1 site📍 Clermont-Ferrand University Hospital, Clermont-Ferrand · Tests: MRI Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer NCT07747740Phase 21 site📍 Moscow Blokhin's Russian Cancer Research Center · Tests: Gemcitabin, Docetaxel, Mitomicin C A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) NCT06637423Phase 1, Phase 213 sites📍 Bakersfield📍 Tampa📍 Chicago Merck Sharp & Dohme LLC · Tests: Sacituzumab tirumotecan, Rescue medication, Supportive care measures FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 NCT05614739Phase 182 sites📍 Tucson📍 Duarte📍 Los Angeles Eli Lilly and Company · Tests: Vepugratinib, Pembrolizumab, enfortumab vedotin, Trastuzumab Deruxtecan, Midazolam Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study NCT07339761NA1 site📍 Aarhus University of Aarhus · Tests: Sexological Support Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer NCT06781879Phase 48 sites📍 Aalborg📍 Aarhus N📍 Herlev Jakob Kristian Jakobsen · Tests: Mitomycin c A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer NCT05521698Phase 16 sites📍 Tucson📍 Los Angeles📍 Bethesda University of Wisconsin, Madison · Tests: Bicalutamide, Biopsy Procedure, Biospecimen Collection, Questionnaire Administration, Transurethral Resection of Bladde… Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC) NCT05825950n/a2 sites📍 Dallas📍 San Antonio University of Texas Southwestern Medical Center Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC) NCT07763197n/a1 site📍 Austin Natera, Inc. Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC? NCT07625527Phase 24 sites📍 Tianjin📍 Tianjin📍 Tianjin Tianjin Medical University Second Hospital · Tests: Active Surveillance, PD-1/PD-L1 Inhibitor-Based Systemic Immunotherapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy